Literature DB >> 22729983

Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

I Peltonen1, T T Myöhänen, P T Männistö.   

Abstract

Prolyl oligopeptidase (PREP) is an intracellular enzyme digesting small proline-containing peptides. Since PREP resides the same brain areas as neurotensin in the nigrostriatal and mesolimbic dopaminergic pathways, we were interested to study if there is an intracellular interaction between them. A colocalization of PREP with neurotensin and neurotensin receptor 1 (NTS1) in the rat striatum, nucleus accumbens (NAcc), substantia nigra (SN) and ventral tegmental area (VTA) was studied with immunofluorescence. From the same brain areas, the levels of dopamine and its metabolites were measured 1 h after the injection of saline, NTS1 ligands (JMV-449; 5 μg) or antagonist (SR142948; 5 μg) to the rat striatum or NAcc. We also studied whether an intraperitoneal injection of a PREP inhibitor (KYP-2047; 5 mg/kg) affects the levels of dopamine and its metabolites alone or modifies the effects of the NTS1 ligands. PREP was highly colocalized with neurotensin and NTS1 in the VTA, and with NTS1 in the SN. Colocalization was moderate or low in other brain areas. When injected to the striatum, JMV-449 had a tendency to increase dopamine (p = 0.052) and metabolite levels in the striatum and SN, whereas SR142948 did not. After the injection to the NAcc, JMV-449 but not SR142948, increased dopamine levels in the VTA and dopamine metabolite levels in the NAcc and VTA. KYP-2047 decreased the dopamine levels in the striatum, but increased dopamine metabolite levels in the NAcc and VTA. Our results suggest a novel role for PREP in the modulation of dopaminergic transmission, which may be different in nigrostriatal and mesolimbic pathways.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22729983     DOI: 10.1007/s11064-012-0825-y

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  42 in total

1.  Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody.

Authors:  A Fassio; G Evans; R Grisshammer; J P Bolam; M Mimmack; P C Emson
Journal:  Neuropharmacology       Date:  2000-06-08       Impact factor: 5.250

Review 2.  Interaction between neurotensin and dopamine in the brain. Morphofunctional and clinical evidence.

Authors:  W Rostène; A Brouard; C Dana; Y Masuo; F Agid; M Vial; A M Lhiaubet; D Pelaprat
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

3.  Cellular distribution of neurotensin receptors in rat brain: immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor.

Authors:  H Boudin; D Pélaprat; W Rostène; A Beaudet
Journal:  J Comp Neurol       Date:  1996-09-09       Impact factor: 3.215

Review 4.  On the role of prolyl oligopeptidase in health and disease.

Authors:  J A García-Horsman; P T Männistö; J I Venäläinen
Journal:  Neuropeptides       Date:  2006-12-29       Impact factor: 3.286

5.  Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats.

Authors:  Aaro J Jalkanen; Katja A Puttonen; Jarkko I Venäläinen; Veijo Sinervä; Anne Mannila; Sirja Ruotsalainen; Elina M Jarho; Erik A A Wallén; Pekka T Männistö
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-02       Impact factor: 4.080

6.  Virally mediated increased neurotensin 1 receptor in the nucleus accumbens decreases behavioral effects of mesolimbic system activation.

Authors:  Ricardo Cáceda; Becky Kinkead; Michael J Owens; Charles B Nemeroff
Journal:  J Neurosci       Date:  2005-12-14       Impact factor: 6.167

7.  Neurochemical consequences following injection of the substance P analogue, DiMe-C7, into the rat ventral tegmental area.

Authors:  J M Barnes; N M Barnes; B Costall; A J Cox; A M Domeney; M E Kelly; R J Naylor
Journal:  Pharmacol Biochem Behav       Date:  1990-12       Impact factor: 3.533

8.  Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons.

Authors:  Fannie St-Gelais; Mark Legault; Marie-Josée Bourque; Pierre-Paul Rompré; Louis-Eric Trudeau
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

9.  Substance P in the rat nucleus accumbens: ultrastructural localization in axon terminals and their relation to dopaminergic afferents.

Authors:  V M Pickel; T H Joh; J Chan
Journal:  Brain Res       Date:  1988-03-22       Impact factor: 3.252

10.  Ability of angiotensin II to modulate striatal dopamine release via the AT1 receptor in vitro and in vivo.

Authors:  D C Brown; L J Steward; J Ge; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

View more
  5 in total

1.  Activation of neurotensin receptor type 1 attenuates locomotor activity.

Authors:  Chelsea A Vadnie; David J Hinton; Sun Choi; YuBin Choi; Christina L Ruby; Alfredo Oliveros; Miguel L Prieto; Jun Hyun Park; Doo-Sup Choi
Journal:  Neuropharmacology       Date:  2014-06-11       Impact factor: 5.250

2.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

3.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

Review 4.  Gut-brain peptides in corticostriatal-limbic circuitry and alcohol use disorders.

Authors:  Chelsea A Vadnie; Jun Hyun Park; Noha Abdel Gawad; Ada Man Choi Ho; David J Hinton; Doo-Sup Choi
Journal:  Front Neurosci       Date:  2014-09-18       Impact factor: 4.677

5.  Therapeutic Effect of Novel Cyanopyrrolidine-Based Prolyl Oligopeptidase Inhibitors in Rat Models of Amnesia.

Authors:  Nikolay N Zolotov; Igor A Schepetkin; Tatyana A Voronina; Vladimir F Pozdnev; Andrei I Khlebnikov; Irina V Krylova; Mark T Quinn
Journal:  Front Chem       Date:  2021-12-22       Impact factor: 5.221

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.